Key terms

About SAGE

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest SAGE news

Apr 30 7:52am ET Novel Postpartum Depression Treatment Offers Upside Potential for Sage Therapeutics (NASDAQ:SAGE) by TipRanks Apr 30 3:00am ET Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE) by TipRanks Apr 26 8:35am ET SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks by TipRanks Apr 26 8:21am ET Sage Therapeutics price target lowered to $25 from $28 at H.C. Wainwright by TipRanks Apr 26 8:08am ET Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment by TipRanks Apr 26 7:58am ET Sage Therapeutics price target lowered to $15 from $26 at RBC Capital by TipRanks Apr 26 7:50am ET Sage Therapeutics price target lowered to $17 from $21 at Canaccord by TipRanks Apr 26 7:29am ET Scotiabank Remains a Buy on SAGE Therapeutics (SAGE) by TipRanks Apr 26 6:46am ET Sage Therapeutics price target lowered to $18 from $20 at Mizuho by TipRanks Apr 26 6:37am ET SAGE Therapeutics (SAGE) Receives a Hold from RBC Capital by TipRanks Apr 26 5:06am ET Sell Rating on Sage Therapeutics Amid Zurzuvae Sales Concerns and Pipeline Risks by TipRanks Apr 26 2:21am ET SAGE Therapeutics’ Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Rating by TipRanks Apr 25 2:25pm ET Hold Rating on SAGE Therapeutics Amid Limited Revenue Prospects and Pipeline Uncertainty by TipRanks Apr 25 2:16pm ET Sage Therapeutics price target lowered to $18 from $22 at Truist by TipRanks Apr 25 11:30am ET Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE) by TipRanks Apr 25 11:12am ET Sage Therapeutics price target lowered to $20 from $26 at Stifel by TipRanks Apr 25 7:55am ET SAGE Therapeutics: Hold Rating Amidst Mixed Financial and Market Signals by TipRanks Apr 25 6:47am ET Sage Therapeutics reports Q1 EPS ($1.80), consensus ($1.65) by TipRanks Apr 22 1:31am ET Analysts Conflicted on These Healthcare Names: SAGE Therapeutics (SAGE), Accolade (ACCD) and Intuitive Surgical (ISRG) by TipRanks Apr 19 11:12am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Apr 19 8:42am ET SAGE Therapeutics Adjusts Inducement Equity Plan and Sets End Date by TipRanks Apr 18 9:23am ET Sage Therapeutics price target lowered to $19 from $34 at Scotiabank by TipRanks Apr 18 7:36am ET Sage Therapeutics price target lowered to $17 from $25 at Oppenheimer by TipRanks Apr 18 7:10am ET Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE), Poseida Therapeutics (PSTX) and Align Tech (ALGN) by TipRanks Apr 18 5:25am ET SAGE Therapeutics: Hold Rating Reiterated Amid Clinical Trial Setbacks and Uncertainties by TipRanks Apr 17 11:30am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Palisade Bio (PALI) by TipRanks Apr 17 11:18am ET H.C. Wainwright concerned over Sage’s next readouts after SAGE-718 miss by TipRanks Apr 17 11:08am ET RBC ‘not altogether surprised’ by Sage move lower after failure in PD by TipRanks Apr 17 9:37am ET Sage Therapeutics cut to Underperform at BofA after Parkinson’s trial fails by TipRanks Apr 17 9:34am ET Sage Therapeutics downgraded to Underperform from Neutral at BofA by TipRanks Apr 17 8:03am ET Sage Therapeutics down 19% at $12.60 after announcing dalzanemdor Phase 2 data by TipRanks
Yesterday 7:30pm ET Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – SAGE by Accesswire Yesterday 7:30am ET Sage Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sage Therapeutics (SAGE) by Accesswire May 04 9:00pm ET Sage Therapeutics, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SAGE by Accesswire May 04 9:00pm ET SAGE ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Sage Therapeutics, Inc. by Accesswire May 04 7:02pm ET SAGE ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Sage Therapeutics, Inc. by Accesswire May 02 4:45pm ET Sage Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - SAGE by Accesswire May 02 4:45pm ET ATTENTION Sage Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights by Accesswire May 02 10:00am ET An Investigation Has Commenced on Behalf of Sage Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SAGE Losses. by Accesswire Apr 30 3:43pm ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE by Newsfile Apr 25 5:15pm ET INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm by Accesswire

SAGE Financials

1-year income & revenue

Key terms

SAGE Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

SAGE Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

People shop in a supermarket in the Manhattan borough of New York city on January 27, 2024. (Photo by Charly TRIBALLEAU / AFP) (Photo by CHARLY TRIBALLEAU/AFP via Getty Images)
Charly Triballeau/AFP/Getty Images
Americans have spent their savings. Economists worry about what comes next
Berkshire Hathaway Chairman Warren Buffett walks through the exhibit hall as shareholders gather to hear from the billionaire investor at Berkshire Hathaway Inc's annual shareholder meeting in Omaha, Nebraska, on May 4, 2019.
Scott Morgan/Reuters/File
Warren Buffett compares AI to nuclear weapons in stark warning
The US Securities and Exchange Commission (SEC) headquarters in Washington, DC, US, on Wednesday, Jan. 10, 2024. The SEC's X account was compromised and a fake post claiming that the agency had green lit plans for a spot-Bitcoin exchange-traded fund fueled a brief surge in the price of the world's biggest cryptocurrency. Photographer: Graeme Sloan/Bloomberg via Getty Images
Graeme Sloan/Bloomberg/Getty Images
Trump Media fires accounting firm after old one accused of being a ‘sham audit mill’
People walk by the New York Stock Exchange (NYSE) on March 06, 2024 in New York City.
Spencer Platt/Getty Images
Three things investors probably don’t know, but should